Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 38, 2008 - Issue 9
126
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Characterization of renal tubular apical efflux of zonampanel, an α-amino-3-hydroxy-5- methylisoxazole-4-propionate receptor antagonist, in humans

, , &
Pages 1191-1202 | Received 24 Mar 2008, Accepted 07 May 2008, Published online: 31 May 2008
 

Abstract

1. Zonampanel, a novel α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor antagonist, is mainly excreted unchanged via renal tubular secretion. The renal apical transport transport of zonampanel was examined in this study using HEK293 cells expressing human organic anion transporter 4 (OAT4/SLC22A11), and membrane vesicles prepared from Sf-9 insect cells expressing human multidrug resistance-associated protein 2 (MRP2/ABCC2), MRP4 (ABCC4), and breast cancer resistance protein (BCRP/ABCG2).

2. Glutaric acid, a model dicarboxylate, trans-stimulated the uptake of [14C]zonampanel by OAT4, suggesting that zonampanel was transported by OAT4 via an exchange with dicarboxylate. Considering the endogenous dicarboxylate gradient, OAT4 seems to transport zonampanel in the direction of reabsorption rather than secretion. For MRP2, MRP4, and BCRP, zonampanel selectively inhibited the activity of MRP4 (Ki = 41.3 µM). Marked transport of [14C]zonampanel was observed only for MRP4 (Km = 33.7 µM).

3. In conclusion, the data indicate that MRP4 was the apical efflux transporter that contributed to the active renal tubular secretion of zonampanel in humans, in concert with the apical reabsorption transporter OAT4 and basolateral uptake transporters.

Declaration of interest:The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.